Business
Aeterna Zentaris Announces Listing Transfer to NASDAQ Capital Market
QUÉBEC CITY, Aug. 28, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\nQUÉBEC CITY, Aug. 28, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that its request to\n transfer its listing to the NASDAQ Capital Market® from the NASDAQ Global Market® has been approved by the NASDAQ Listing Qualifications Staff. The\n Company's securities will begin trading on the NASDAQ Capital Market\n effective at the opening of trading on Thursday, August 29, 2013. The\n transfer of the Company's listing to the NASDAQ Capital Market is not\n expected to have any impact on trading in the Company's shares, and the\n Company's shares will continue to trade on NASDAQ under the symbol AEZS\n and with the same CUSIP number of 007975303.\n\n\nAbout Aeterna Zentaris Inc. \n\n\nAeterna Zentaris is a specialty biopharmaceutical company engaged in\n developing novel treatments in oncology and endocrinology. The\n Company's pipeline encompasses compounds from drug discovery to\n regulatory approval. For more information, visit www.aezsinc.com.\n\n\nForward-Looking Statements \n\n\nThis press release contains forward-looking statements made pursuant to\n the safe harbour provisions of the U.S. Securities Litigation Reform\n Act of 1995, including forward-looking statements relating to the\n expected impact of the transfer of the listing of the Company's shares\n on the NASDAQ Capital Market. Forward-looking statements involve known\n and unknown risks and uncertainties that could cause the Company's\n actual results to differ materially from those in the forward-looking\n statements. Such risks and uncertainties include, among others, market\n reaction to the transfer of the listing of the shares on the NASDAQ\n Capital Market, the availability of funds and resources to pursue R&D\n projects, the successful and timely completion of clinical studies, the\n risk that safety and efficacy data from any of our Phase 3 trials may\n not coincide with the data analyses from previously reported Phase 1\n and/or Phase 2 clinical trials, the ability of the Company to take\n advantage of business opportunities in the pharmaceutical industry,\n uncertainties related to the regulatory process and general changes in\n economic conditions.\nInvestors should consult the Company's quarterly and annual filings with\n the Canadian and U.S. securities commission...